Lipoprotein-Associated Phospholipase A2 and Its Association With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) Trial

Background— Lipoprotein-associated phospholipase A2 (Lp-PLA2) is associated with the risk of cardiovascular (CV) events in population-based studies. The prognostic value of Lp-PLA2 in patients with acute coronary syndromes (ACS) has not been established. Methods and Results— Plasma levels of Lp-PLA2 activity were measured at baseline (n=3648) and 30 days (n=3265) in patients randomized to atorvastatin 80 mg/d or pravastatin 40 mg/d after ACS in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction) trial. The primary end point was death, myocardial infarction, unstable angina, revascularization, or stroke (mean follow-up 24 months). At baseline after ACS, the risk of recurrent CV events was similar across all quintiles of Lp-PLA2 activity (Ptrend=0.88). Overall, mean levels of Lp-PLA2 were lower at 30 days of follow-up than at baseline (35.7 versus 40.9 nmol · min−1 · mL−1, P<0.001). In particular, treatment with atorvastatin 80 mg/d was associated with a 20% reduction in Lp-PLA2 activity (P<0.001), whereas Lp-PLA2 rose 3.6% with pravastatin 40 mg/d (P<0.001). Patients with 30-day Lp-PLA2 activity in the highest quintile were at significantly increased risk of recurrent CV events compared with those in the lowest quintile (26.4% versus 17.6%, Ptrend=0.002). After adjustment for cardiac risk factors, treatments, achieved low-density lipoprotein (LDL), and C-reactive protein, Lp-PLA2 activity in the highest quintile remained independently associated with a higher risk of recurrent CV events (adjusted hazard ratio 1.33, 95% confidence interval [CI] 1.01 to 1.74). Conclusions— Lp-PLA2 is not useful for risk stratification when measured early after ACS. At 30 days, Lp-PLA2 activity is significantly lowered with high-dose statin therapy and is associated with an increased risk of CV events independent of C-reactive protein and LDL cholesterol levels.

[1]  M. Elisaf,et al.  Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. , 2005, Clinical chemistry.

[2]  P. Ridker,et al.  The effect of statin therapy on lipoprotein associated phospholipase A2 levels. , 2005, Atherosclerosis.

[3]  H. Brenner,et al.  Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. , 2005, Atherosclerosis.

[4]  P. Austin,et al.  Impact of the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22/Reversal of Atherosclerosis With Aggressive Lipid Lowering Trials on Trends in Intensive Versus Moderate Statin Therapy in Ontario, Canada , 2005, Circulation.

[5]  R. Sacco,et al.  Interleukin-2 levels are associated with carotid artery intima-media thickness. , 2005, Atherosclerosis.

[6]  E. Schaefer,et al.  Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. , 2005, The American journal of cardiology.

[7]  W. März,et al.  Platelet-Activating Factor Acetylhydrolase Activity Indicates Angiographic Coronary Artery Disease Independently of Systemic Inflammation and Other Risk Factors: The Ludwigshafen Risk and Cardiovascular Health Study , 2005, Circulation.

[8]  A. Hofman,et al.  Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study , 2005, Circulation.

[9]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[10]  D. Jacobs,et al.  Association of Lipoprotein-Associated Phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults: The CARDIA Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[11]  E. Brilakis,et al.  Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. , 2005, European heart journal.

[12]  C. Meisinger,et al.  Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany , 2004, Circulation.

[13]  A. M. Leone,et al.  Widespread Myocardial Inflammation and Infarct-Related Artery Patency , 2004, Circulation.

[14]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[15]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[16]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[17]  Hung‐Yuan Cheng,et al.  The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. , 2003, Bioorganic & medicinal chemistry letters.

[18]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[19]  F. Crea,et al.  Widespread coronary inflammation in unstable angina. , 2003, The New England journal of medicine.

[20]  J. Goudevenos,et al.  Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[21]  R. Wolfert,et al.  Lp-PLA2: an emerging biomarker of coronary heart disease , 2002, Expert review of molecular diagnostics.

[22]  J. Manson,et al.  A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. , 2001, Journal of the American College of Cardiology.

[23]  D. Stengel,et al.  Prevents Injury-induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Acetylhydrolase − Adenovirus-mediated Gene Transfer of Human Platelet-activating Factor Adenovirus-mediated Gene Transfer of Human Platelet-activating Factor–acetylhydrolase Prevents Injury-induced Neointima Forma , 2022 .

[24]  H. Krumholz.  Lipoprotein-Associated Phospholipase A , 2001 .

[25]  L. Tjoelker,et al.  Platelet-activating factor acetylhydrolases in health and disease. , 2000, Biochimica et biophysica acta.

[26]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[27]  C. Packard,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease , 2000 .

[28]  M. H.,et al.  LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 AS AN INDEPENDENT PREDICTOR OF CORONARY HEART DISEASE , 2000 .

[29]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[30]  Yasuo Ikeda,et al.  Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. , 1999, Biochemical and biophysical research communications.

[31]  P. Peplow.  Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[32]  M. Liu,et al.  Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma. , 1999, Biochimica et biophysica acta.

[33]  K. Feingold,et al.  In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[35]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[36]  M. Elisaf,et al.  Increased activity of platelet‐activating factor acetylhydrolase in low‐density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia , 1997, European journal of clinical investigation.

[37]  M. Liu,et al.  Disparate effects of oxidation on plasma acyltransferase activities: inhibition of cholesterol esterification but stimulation of transesterification of oxidized phospholipids. , 1996, Biochimica et biophysica acta.

[38]  G. Zimmerman,et al.  Anti-inflammatory properties of a platelet-activating factor acetylhydrolase , 1995, Nature.

[39]  R. Krauss,et al.  Modification of LCAT activity and HDL structure. New links between cigarette smoke and coronary heart disease risk. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[40]  R. Taylor,et al.  Variation in plasma platelet‐activating factor degradation and serum lipids after acute myocardial infarction , 1993, Coronary artery disease.

[41]  G. Zimmerman,et al.  Human macrophages secret platelet-activating factor acetylhydrolase. , 1990, The Journal of biological chemistry.

[42]  G. Zimmerman,et al.  Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[43]  R. Scragg,et al.  Changes in serum lipid concentrations during first 24 hours after myocardial infarction. , 1987, British medical journal.